RNA Lipoplex Formulation for Stable Storage and IV Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for formulations that efficiently deliver biologically active RNA to target tissues while maintaining product quality and biological activity, particularly for use in GMP-compliant manufacturing with long shelf-life and stability.
Innovation Solution
The development of RNA lipoplex particles comprising specific ratios of cationic and additional lipids, sodium chloride, and stabilizers, along with controlled manufacturing processes, enables efficient delivery and storage of RNA, including freeze-drying and spray-drying methods to extend shelf-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA is delivered using conventional lipoplex formulations, then RNA delivery to target tissues is achieved, but product quality and biological activity are lost during storage
Solution Approach 1:
The patent applies parameter changes by optimizing the charge ratio between cationic lipids and RNA to a specific range (1:1.9 to 1:2.1), adjusting lipid composition ratios, and controlling formulation pH to achieve both effective RNA delivery and enhanced storage stability. These parameter optimizations resolve the contradiction by creating a formulation that maintains biological activity throughout extended storage periods.
Solution Approach 2:
The invention uses composite materials by combining cationic lipids with specific helper lipids in defined ratios within the liposome structure. This composite approach creates a stable lipoplex formulation that protects RNA during storage while maintaining delivery functionality, thereby extending shelf-life without compromising product quality.
2Duration of action of stationary object
If RNA lipoplex formulations are stored liquid, then ease of administration is maintained, but shelf-life is limited
Solution Approach 1:
The patent utilizes phase transitions by developing a liquid crystalline liposome formulation that maintains a defined phase state during storage. This phase transition approach allows the formulation to be stored as a stable liquid or frozen state with extended shelf-life, while still enabling easy reconstitution and administration when needed.
3Manufacturing precision
If GMP-compliant manufacturing is implemented, then product quality is ensured, but manufacturing complexity increases
Solution Approach 1:
The invention simplifies GMP-compliant manufacturing by establishing specific parameter ranges for charge ratio (1:1.9 to 1:2.1), lipid composition, and pH that can be controlled through standardized processes. These defined parameters enable consistent batch-to-batch production while maintaining regulatory compliance, reducing the complexity of manufacturing control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations maintain RNA activity and product quality, allowing for stable delivery and storage, suitable for GMP compliance and intravenous administration.
Implementation Method 1
RNA is bound to liposomes composed of a mixture of a cationic lipid and helper lipid to form injectable nanoparticle formulations
Implementation Method 2
The formulations maintain RNA activity and product quality, allowing for stable delivery and storage
Implementation Method 3
RNA lipoplex particle formulations described herein can be frozen or dehydrated by freeze-drying, spray-drying or related methods, enabling to obtain extended shelf-life of the products
Implementation Method 4
RNA lipoplex particle formulations described herein can be frozen or dehydrated by freeze-drying, spray-drying or related methods, enabling to obtain extended shelf-life of the products
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.